﻿<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article xml:lang="en" article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">J Rheum Dis</journal-id>
<journal-title-group>
<journal-title>Journal of Rheumatic Diseases</journal-title>
<abbrev-journal-title abbrev-type="publisher">J Rheum Dis</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2093-940X</issn>
<issn pub-type="epub">2233-4718</issn>
<publisher>
<publisher-name>Korean College of Rheumatology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.4078/jrd.2024.0144</article-id>
<article-id pub-id-type="publisher-id">jrd-32-3-225</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Resolution of long-lasting laryngeal manifestations using glucocorticoids and tumor necrosis factor-&#945; inhibitor therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-0569-0433</contrib-id>
<name><surname>Suzuki</surname><given-names>Tomohiro</given-names></name>
<degrees>M.D.</degrees>
<xref rid="aff1" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5890-3606</contrib-id>
<name><surname>Komai</surname><given-names>Toshihiko</given-names></name>
<degrees>M.D., Ph.D.</degrees>
<xref rid="aff1" ref-type="aff">1</xref>
<xref rid="cor1" ref-type="corresp"/>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-6374-5777</contrib-id>
<name><surname>Koyama</surname><given-names>Misaki</given-names></name>
<degrees>M.D.</degrees>
<xref rid="aff2" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0425-1010</contrib-id>
<name><surname>Koda</surname><given-names>Kento</given-names></name>
<degrees>M.D.</degrees>
<xref rid="aff2" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0608-7237</contrib-id>
<name><surname>Ueha</surname><given-names>Rumi</given-names></name>
<degrees>M.D., Ph.D.</degrees>
<xref rid="aff2" ref-type="aff">2</xref>
<xref rid="aff3" ref-type="aff">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1536-0303</contrib-id>
<name><surname>Shoda</surname><given-names>Hirofumi</given-names></name>
<degrees>M.D., Ph.D.</degrees>
<xref rid="aff1" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7276-5254</contrib-id>
<name><surname>Fujio</surname><given-names>Keishi</given-names></name>
<degrees>M.D., Ph.D.</degrees>
<xref rid="aff1" ref-type="aff">1</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>Department of Allergy and Rheumatology, Graduate School of Medicine, Tokyo, <country>Japan</country></aff>
<aff id="aff2"><label>2</label>Department of Otolaryngology and Head and Neck Surgery, The University of Tokyo, Tokyo, <country>Japan</country></aff>
<aff id="aff3"><label>3</label>Swallowing Center, The University of Tokyo Hospital, Tokyo, <country>Japan</country></aff>
<author-notes>
<corresp id="cor1">
<bold>Corresponding author:</bold> Toshihiko Komai, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-5890-3606">https://orcid.org/0000-0001-5890-3606</ext-link> Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. <bold>E-mail:</bold> <email xlink:href="KOMAIT-INT@h.u-tokyo.ac.jp">KOMAIT-INT@h.u-tokyo.ac.jp</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>1</day>
<month>7</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>3</month>
<year>2025</year>
</pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage>225</fpage>
<lpage>228</lpage>
<history>
<date date-type="received">
<day>9</day>
<month>12</month>
<year>2024</year>
</date>
<date date-type="rev-recd">
<day>12</day>
<month>2</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>3</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#169; 2025 by The Korean College of Rheumatology. All rights reserved.</copyright-statement>
<copyright-year>2025</copyright-year>
<license license-type="open-access">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is a rare disorder characterized by features of both relapsing polychondritis (RP) and Beh&#231;et&#8217;s disease (BD), with multi-organ involvement, including inflammation and destruction of cartilaginous tissues. This report describes a patient with MAGIC syndrome who responded to immunosuppressive therapy for long-lasting laryngeal inflammation and provides the first description of a patient with MAGIC syndrome positive for human leukocyte antigen (HLA)-A26. Here we present a 49-year-old male with recurrent oral and genital ulcers, hoarseness, and swallowing difficulties. Laryngoscopy showed bilateral vocal fold immobility, and contrast-enhanced magnetic resonance imaging (MRI) demonstrated inflammation in the cricoid, arytenoid, and auricular cartilages. The patient was diagnosed with MAGIC syndrome based on the presence of both RP and BD criteria. Treatment with high-dose corticosteroids and adalimumab biosimilar resulted in significant improvement in hoarseness and MRI findings of cartilage inflammation. This case highlights the effective use of immunosuppressive therapy for managing long-lasting laryngeal involvement in MAGIC syndrome, potentially avoiding the need for invasive interventions such as tracheostomy.</p>
</abstract>
<kwd-group>
<kwd>Mouth and genital ulcers with inflamed cartilage syndrome</kwd>
<kwd>Beh&#231;et&#8217;s disease</kwd>
<kwd>Relapsing polychondritis</kwd>
<kwd>Hoarseness</kwd>
<kwd>Vocal cords</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>Relapsing polychondritis (RP) is characterized by inflammation and destruction of cartilaginous tissues and affects a variety of organs including the ears, eyes, nose, peripheral joints, tracheobronchial tree, larynx, and blood vessels [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>]. Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is a rare entity that exhibits the clinical features of both RP and Beh&#231;et&#8217;s disease (BD). A recent observational cohort and systematic review indicated that MAGIC syndrome preferentially involves the ocular, cutaneous, gastrointestinal, and central nervous systems, with a higher prevalence of aortitis, Raynaud phenomenon, and anti-collagen type II antibodies compared with non-MAGIC RP; however, laryngeal involvement in MAGIC syndrome has not been clearly reported [<xref rid="ref1" ref-type="bibr">1</xref>]. Here, we report the patient with MAGIC syndrome to undergo effective immunosuppressive therapy for long-lasting laryngeal inflammation; treatment efficacy is demonstrated using images from before and after treatment. This is also the first report to describe a patient with MAGIC syndrome who is positive for human leukocyte antigen (HLA)-A26.</p>
</sec>
<sec sec-type="cases">
<title>CASE REPORT</title>
<p>A 49-year-old male with a history of recurrent noninfectious genital ulcers was referred to our department for recurrent painful oral ulcers for 20 years, worsening hoarseness for 4 years, and swallowing difficulty for 1 year. The cause of these symptoms had not been determined at other hospitals, and although tracheostomy was recommended, the patient refused this intervention. Three months prior to referral, he was diagnosed with a benign esophageal ulcer that improved after taking vonoprazan. This retrospective chart review and publication were approved by the Ethics Committee of The University of Tokyo (approval number: 11592). Written informed consent was obtained from the patient.</p>
<p>Upon presentation to our department, the patient described hoarseness and difficulty breathing with exertion. Physical examination revealed oral ulcers and a skin rash similar to folliculitis on his left lower leg, but genital ulcers and auricular abnormalities were not observed. Laboratory investigation revealed a normal erythrocyte sedimentation rate and C-reactive protein level; autoantibodies (including rheumatoid factor, antinuclear antibody, and antineutrophil cytoplasmic antibody) were not detected. Viral tests for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus, along with a T-SPOT test for mycobacterial infection, were all negative. Furthermore, electromyography tests on the sternocleidomastoid and orbicularis oris muscles were normal, and a repetitive stimulation study of the facial and accessory nerves showed no evidence of waning. Serologic HLA analysis demonstrated A24, A26, B54, and B61. Laryngoscopy revealed bilateral vocal fold immobility with impairment of adduction and abduction (<xref rid="F1" ref-type="fig">Figure 1A</xref> and <xref rid="S1" ref-type="supplementary-material">Supplementary Video 1</xref>). Contrast-enhanced magnetic resonance imaging (MRI) demonstrated inflammation in the cricoid and arytenoid cartilages, the surrounding tissue, and bilateral auricular cartilages (<xref rid="F1" ref-type="fig">Figure 1B</xref> and <xref rid="F1" ref-type="fig">1C</xref>). We could not biopsy the patient&#8217;s laryngeal cartilage because he did not give consent, and histologic examination of an auricular cartilage biopsy did not reveal chondritis. He met the diagnostic criteria for BD established by the Beh&#231;et&#8217;s Disease Research Committee of Japan [<xref rid="ref3" ref-type="bibr">3</xref>] and had auricular and laryngotracheal chondritis detected by MRI.</p>
<p>The patient&#8217;s oral ulcers and difficulty breathing with exertion gradually decreased over 1 month of treatment with prednisolone (1 mg/kg/day). His hoarseness, measured by a visual analogue scale, decreased from a score of 73/100 before treatment to 37/100 at 1 month after starting treatment. Contrast-enhanced MRI 4 weeks after starting treatment demonstrated improvement of the inflammation in the laryngeal and auricular cartilages (<xref rid="F2" ref-type="fig">Figure 2A</xref> and <xref rid="F2" ref-type="fig">2B</xref>). Since his laryngotracheal and auricular chondritis responded to corticosteroids, the diagnosis of RP was made according to Damiani&#8217;s diagnostic criteria [<xref rid="ref4" ref-type="bibr">4</xref>], and the patient was diagnosed with MAGIC syndrome.</p>
<p>Follow-up laryngoscopy performed 3 months after starting treatment revealed improvement in bilateral vocal fold mobility (<xref rid="F2" ref-type="fig">Figure 2C</xref> and <xref rid="S1" ref-type="supplementary-material">Supplementary Video 2</xref>). The patient&#8217;s long-lasting clinical findings had improved with prednisolone, and the addition of an adalimumab biosimilar allowed us to taper the glucocorticoid dose. After approximately 1 year, prednisolone was successfully tapered off, with continued treatment using adalimumab biosimilar at a dose of 40 mg biweekly. His clinical findings have remained stable, and the glucocorticoid dose has been successfully reduced and discontinued with no exacerbation of laryngeal symptoms.</p>
</sec>
<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>Approximately half of patients with RP have laryngeal involvement and often manifest symptoms such as hoarseness, dyspnea, cough, and stridor; tracheostomy is occasionally required to avoid serious complications [<xref rid="ref2" ref-type="bibr">2</xref>]. In contrast, only 3 of the 45 previously reported patients with MAGIC syndrome had laryngeal inflammation [<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr"/>-<xref rid="ref7" ref-type="bibr">7</xref>], and only two of them underwent tracheostomy [<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref7" ref-type="bibr">7</xref>]. Our patient experienced hoarseness for 4 years, but his laryngeal symptoms that were later diagnosed as being associated with MAGIC syndrome resolved with immunosuppressive therapy; tracheostomy was not required. As tracheostomy is associated with an increase in short-term mortality [<xref rid="ref2" ref-type="bibr">2</xref>], this patient&#8217;s therapeutic response, even with long-lasting laryngeal inflammation, provides useful knowledge for clinicians.</p>
<p>This patient&#8217;s diagnosis was ultimately determined to be MAGIC syndrome but considering the episodic and relapsing nature of both BD and RP, as well as the diagnostic challenges posed by their overlapping features, the possibility that cartilage inflammation in BD may be misinterpreted as RP remains. One study demonstrated that imaging findings from CT and MRI correlate more strongly with clinical markers of disease activity in RP than with inflammatory laboratory markers [<xref rid="ref8" ref-type="bibr">8</xref>]. This observation underscores the clinical value of imaging modalities such as MRI in diagnosing conditions like MAGIC syndrome, especially when histopathological confirmation is not available.</p>
<p>HLA typing revealed that this patient with MAGIC syndrome had HLA-A26, which is associated with the coexistence of uveitis and gastrointestinal involvement in patients with BD [<xref rid="ref9" ref-type="bibr">9</xref>]. However, our patient had gastrointestinal involvement but not uveitis. Since HLA-A26 is associated with uveitis and its severity in BD patients with HLA-B51 [<xref rid="ref9" ref-type="bibr">9</xref>] and considering the importance of strong immunosuppression to evaluate the effects of long-lasting inflammation in this patient, we determined the therapeutic strategy. Given the overlap in immunological backgrounds and clinical features between BD and RP, patients with MAGIC syndrome harboring HLA-A26 have not been documented previously [<xref rid="ref10" ref-type="bibr">10</xref>], further research is needed to better understand this relationship, especially in the context of MAGIC syndrome.</p>
</sec>
<sec sec-type="summary">
<title>SUMMARY</title>
<p>This case highlights the importance of imaging studies for a patient with hoarseness to evaluate for laryngeal inflammation. It also demonstrates that immunosuppressive therapy may be effective, even for patients with longstanding laryngeal chondritis.</p>
</sec>
<sec sec-type="supplementary-material">
<title>SUPPLEMENTARY DATA</title>
<p>Supplementary data can be found with this article online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4078/jrd.2024.0144">https://doi.org/10.4078/jrd.2024.0144</ext-link></p>
<p>Supplementary Video 1. Bilateral vocal fold movements are impaired in both adduction and abduction.</p>
<p>Supplementary Video 2. Bilateral vocal fold movement impairment is markedly improved.</p>
<supplementary-material id="S1" content-type="local-data">
<media xlink:href="jrd-32-3-225-supplevideo1.mp4" mimetype="video" mime-subtype="mp4"/>
</supplementary-material>
<supplementary-material id="S2" content-type="local-data">
<media xlink:href="jrd-32-3-225-supplevideo2.mp4" mimetype="video" mime-subtype="mp4"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGMENTS</title>
<p>None.</p>
</ack>
<fn-group>
<fn fn-type="supported-by">
<p><bold>FUNDING</bold></p>
<p>None.</p>
</fn>
<fn fn-type="coi-statement">
<p><bold>CONFLICT OF INTEREST</bold></p>
<p>TK has received speaking fees and/or honoraria from Tanabe Mitsubishi, Pfizer, AbbVie, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Novartis, Taisho Pharmaceutical, and Janssen and received grants and speaking fees from GlaxoSmithKline. HS has received fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Sanofi, AbbVie, GlaxoSmithKline, Gilead, Boehringer Ingelheim, Jansen, Novartis, Chugai, Astellas, Eisai, Asahi Kasei, Taisho Pharmaceutical, AstraZeneca, and Daiichi-Sankyo. KF has received speaking fees and/or honoraria from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, Taisho, and AstraZeneca and has received research grants from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Eisai, Tsumura, AbbVie, and Asahi Kasei. The other authors do not have potential conflicts of interest relevant to this article.</p>
</fn>
<fn fn-type="con">
<p><bold>AUTHOR CONTRIBUTIONS</bold></p>
<p>TS and TK contributed to manuscript writing (original draft preparation), conceptualization, and visualization. MK, RU, HS, and KF contributed to manuscript writing (reviewing and editing). MK, KK, and RU contributed to collection of patient data. All authors have read and approved the final manuscript.</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Luo</surname><given-names>Y</given-names></name>
<name><surname>Bolek</surname><given-names>EC</given-names></name>
<name><surname>Quinn</surname><given-names>KA</given-names></name>
<name><surname>Wells</surname><given-names>K</given-names></name>
<name><surname>Rose</surname><given-names>E</given-names></name>
<name><surname>Sikora</surname><given-names>K</given-names></name>
<etal/>
</person-group>
<year>2022</year>
<article-title>A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome</article-title>
<source>Semin Arthritis Rheum</source>
<volume>52</volume>
<elocation-id>151924</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.semarthrit.2021.10.007</pub-id>
<pub-id pub-id-type="pmid">34972595</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yin</surname><given-names>R</given-names></name>
<name><surname>Xu</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Zhang</surname><given-names>F</given-names></name>
<etal/>
</person-group>
<year>2024</year>
<article-title>Predictors and prognosis of tracheostomy in relapsing polychondritis</article-title>
<source>Rheumatology (Oxford)</source>
<volume>63</volume>
<fpage>3042</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1093/rheumatology/kead588</pub-id>
<pub-id pub-id-type="pmid">37934151</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki Kurokawa</surname><given-names>M</given-names></name>
<name><surname>Suzuki</surname><given-names>N</given-names></name>
</person-group>
<year>2004</year>
<article-title>Behcet&#39;s disease</article-title>
<source>Clin Exp Med</source>
<volume>4</volume>
<fpage>10</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1007/s10238-004-0033-4</pub-id>
<pub-id pub-id-type="pmid">15598081</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Damiani</surname><given-names>JM</given-names></name>
<name><surname>Levine</surname><given-names>HL</given-names></name>
</person-group>
<year>1979</year>
<article-title>Relapsing polychondritis--report of ten cases</article-title>
<source>Laryngoscope</source>
<volume>89</volume>
<issue>6 Pt 1</issue>
<fpage>929</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1288/00005537-197906000-00009</pub-id>
<pub-id pub-id-type="pmid">449538</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Fei</surname><given-names>Y</given-names></name>
<name><surname>Shen</surname><given-names>M</given-names></name>
<name><surname>Wu</surname><given-names>H</given-names></name>
<etal/>
</person-group>
<year>2021</year>
<article-title>Anaplastic large cell lymphoma in a patient with MAGIC syndrome: a case and review of the literature</article-title>
<source>Clin Rheumatol</source>
<volume>40</volume>
<fpage>2075</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1007/s10067-020-05384-x</pub-id>
<pub-id pub-id-type="pmid">32914210</pub-id>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Geissal</surname><given-names>ED</given-names></name>
<name><surname>Wernick</surname><given-names>R</given-names></name>
</person-group>
<year>2010</year>
<article-title>A case of severe MAGIC syndrome treated successfully with the tumor necrosis factor-alpha inhibitor infliximab</article-title>
<source>J Clin Rheumatol</source>
<volume>16</volume>
<fpage>185</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1097/RHU.0b013e3181dfce16</pub-id>
<pub-id pub-id-type="pmid">20414125</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Abduljalil</surname><given-names>M</given-names></name>
<name><surname>Alsaied</surname><given-names>A</given-names></name>
<name><surname>Bella</surname><given-names>A</given-names></name>
</person-group>
<year>2019</year>
<article-title>Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome in pregnancy</article-title>
<source>Bahrain Med Bull</source>
<volume>41</volume>
<fpage>281</fpage>
<lpage>4</lpage>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Thaiss</surname><given-names>WM</given-names></name>
<name><surname>Nikolaou</surname><given-names>K</given-names></name>
<name><surname>Spengler</surname><given-names>W</given-names></name>
<name><surname>Spira</surname><given-names>D</given-names></name>
<name><surname>Xenitidis</surname><given-names>T</given-names></name>
<name><surname>Henes</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<year>2016</year>
<article-title>Imaging diagnosis in relapsing polychondritis and correlation with clinical and serological data</article-title>
<source>Skeletal Radiol</source>
<volume>45</volume>
<fpage>339</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1007/s00256-015-2270-x</pub-id>
<pub-id pub-id-type="pmid">26490679</pub-id>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nakajima</surname><given-names>T</given-names></name>
<name><surname>Tsuji</surname><given-names>H</given-names></name>
<name><surname>Inaba</surname><given-names>R</given-names></name>
<name><surname>Saito</surname><given-names>R</given-names></name>
<name><surname>Nishimura</surname><given-names>K</given-names></name>
<name><surname>Morinobu</surname><given-names>A</given-names></name>
</person-group>
<year>2024</year>
<article-title>Significant association of HLA-A26 with uveitis and gastrointestinal involvement in patients with Beh&#231;et&#39;s disease in a multicentre study</article-title>
<source>Mod Rheumatol</source>
<volume>34</volume>
<fpage>1221</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1093/mr/roae022</pub-id>
<pub-id pub-id-type="pmid">38482606</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shimizu</surname><given-names>J</given-names></name>
<name><surname>Murayama</surname><given-names>MA</given-names></name>
<name><surname>Mizukami</surname><given-names>Y</given-names></name>
<name><surname>Arimitsu</surname><given-names>N</given-names></name>
<name><surname>Takai</surname><given-names>K</given-names></name>
<name><surname>Miyabe</surname><given-names>Y</given-names></name>
</person-group>
<year>2023</year>
<article-title>Innate immune responses in Beh&#231;et disease and relapsing polychondritis</article-title>
<source>Front Med (Lausanne)</source>
<volume>10</volume>
<elocation-id>1055753</elocation-id>
<pub-id pub-id-type="doi">10.3389/fmed.2023.1055753</pub-id>
<pub-id pub-id-type="pmid">37435539</pub-id>
<pub-id pub-id-type="pmcid">PMC10331610</pub-id>
</element-citation>
</ref>
</ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Laryngoscopy and magnetic resonance imaging (MRI) before treatment. (A) Laryngoscopy reveals restricted abduction of both vocal cords on inhalation. (B, C) Contrast-enhanced MRI demonstrates thickening and increased enhancement of the arytenoid and cricoid cartilages (B, indicated by the arrow) and bilateral auricular cartilages (C, indicated by the arrows).</p>
</caption>
<graphic xlink:href="jrd-32-3-225-f1.tif"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Laryngoscopy and magnetic resonance imaging (MRI) after treatment. (A, B) Four weeks after starting treatment, contrast-enhanced MRI demonstrates improvement in the thickening and enhancement of the arytenoid and cricoid cartilages (A) and bilateral auricular cartilages (B). (C) Three months after starting treatment, laryngoscopy reveals improved vocal cord abduction on inhalation.</p>
</caption>
<graphic xlink:href="jrd-32-3-225-f2.tif"/>
</fig>
</sec>
</back>
</article>